Agenus Inc. (AGEN) intrinsic value & 10-year financials

Agenus Inc. (AGEN) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue grew 19.7% a year to $114.2M, with an average return on invested capital of -57.7%.

Graham intrinsic value
—
Share price (Oct 17, 2026)
$6.04
Market cap
$179.6M
Revenue (FY2025)
$114.2M
Revenue growth (10-yr CAGR)
19.7%
ROIC (10-yr avg)
-57.7%
Free cash flow (FY2025)
-$77.2M

AGEN 10-year financial history

Fiscal year Revenue Net income EPS (diluted) Free cash flow Operating margin ROIC
FY2025 $114.2M -$3.1M $0.00 -$77.2M -17.7% 8.1%
FY2024 $103.5M -$232.3M -$10.59 -$158.9M -116.4% 47.9%
FY2023 $156.3M -$257.4M -$0.01 -$234.2M -102.1% 70.9%
FY2022 $98.0M -$230.7M -$0.01 -$228.4M -183.0% 76.2%
FY2021 $295.7M -$28.7M -$0.00 -$23.7M 8.7% -9.8%
FY2020 $88.2M -$182.9M -$0.02 -$142.6M -133.0% 42.1%
FY2019 $150.0M -$111.6M — -$23.3M -46.7% 28.9%
FY2018 $36.8M -$162.0M — -$134.7M -336.6% 133.8%
FY2017 $42.9M -$120.7M — -$97.3M -242.1% -440.4%
FY2016 $22.6M -$127.0M — -$92.5M -476.1% -534.3%

Source: annual 10-K filings on SEC EDGAR. Figures in USD.

Executive summary

AGENUS INC is a consistent compounder, expanding top-line revenue at 19.7% annually over the past decade.

AGENUS INC has earned high returns on invested capital, averaging 38.8% ROIC over the available history. High ROIC is consistent with a durable franchise, but it is not by itself proof of an economic moat.

AGENUS INC has not shown aggressive share repurchases (>10% retirement) or a major balance-sheet leverage increase (>50% net debt growth) over the 10-year window.

Benjamin Graham lens

Under Benjamin Graham's formula using SEC EDGAR fundamentals, AGENUS INC is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $0.00 per share.

AGEN stock: frequently asked questions

What is the intrinsic value of Agenus Inc. (AGEN) stock?

Graham's formula only works with positive earnings. Agenus Inc. reported diluted EPS of $0.00 in fiscal 2025, so no Graham value is shown. The 10-year table shows revenue and cash-flow trends instead.

How fast has Agenus Inc. grown?

Revenue went from $22.6M in fiscal 2016 to $114.2M in fiscal 2025, a compound annual growth rate of 19.7%. Net income was -$3.1M in fiscal 2025.

Does Agenus Inc. generate free cash flow?

Agenus Inc. generated -$77.2M of free cash flow (operating cash flow minus capital expenditures) in fiscal 2025. Free cash flow was positive in 0 of the last 10 reported years.

What is AGEN's return on invested capital?

Average ROIC over the last 10 fiscal years was -57.7%, and average return on equity was 288.8%. Sustained ROIC above about 15% usually points to a durable competitive advantage.

Where does this AGEN data come from?

From Agenus Inc.'s annual 10-K filings on SEC EDGAR, most recently filed May 11, 2026. Prices are end-of-day snapshots; valuations are formula outputs, not investment advice.

Similar biological products stocks